Special: Buy These 3 Cryptos to Beat Bitcoin

SCORE

70

SUPN: Supernus Pharmaceuticals, Inc. is a Buy


The current rating for SUPN is 70, which is 40% above its historic median rating of 50. This indicates lower risk than normal.


The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.